BioSpace News Archive

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, announced that company management will be presenting at the Raymond James’ Human Health Innovation Conference on Thursday June 18, 2020 at 8:20 a.m. ET.

Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces that on June 5, 2020 it has entered into a privately negotiated agreement with a holder of its outstanding 5.75% Convertible Senior Notes due 2021.

The first healthy volunteer has been dosed in a Phase 1 study of JS016, the lead antibody from Lilly’s collaboration with Junshi Biosciences

Can-Fite BioPharma Ltd. announced that the Company’s VP of Business Development, Dr. Sari Fishman, is conducting one-on-one meetings with pharmaceutical companies for potential distribution and partnerships for the Company’s drug candidates, Piclidenoson and Namodenoson, at the BIO International Convention 2020 which is taking place digitally on June 8-12, 2020.

Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has completed enrollment in the low-dose cohort of the Phase 1/2 (“Stage 1”) study for Type II

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that The Lancet Oncology has published results from the INVICTUS pivotal Phase 3 study of QINLOCK in patients with fourth-line gastrointestinal stromal tumor (GIST).

Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Initial Targeted Engagement for Regulatory Advice (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel wound care and biosurgical devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the Virtual Investor Fireside Chat Series on Monday, June 15, 2020 at 12:00 PM ET.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced that Greg Divis, Chief Executive Officer of Avadel, and Jordan Dubow, M.D., Chief Medical Officer of Avadel, will present a corporate overview at BIO Digital from June 8-12, 2020. The presentation wil

Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics company, to use Teneobio’s Heavy Chain Antibodies (UniAbs ® ) for Intellia’s next generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs ® against targets which can be used in engineered cell therapies for various life-threateni